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ABSTRACT: In the US, rabies virus (RV) has been enzootic in raccoons (Procyon lotor) since the late
1940s. Oral rabies vaccination (ORV) was implemented in the 1990s to halt the spread of raccoon RV
and continues to be used as a wildlife management tool. Our objective was to evaluate a recombinant
human adenovirus–rabies virus glycoprotein vaccine in northern New York, Vermont, and New
Hampshire over a 3-yr period, using changes in RV neutralizing antibody (RVNA) seroprevalence in
raccoon populations as an immunologic index of ORV impact. Vaccine baits were distributed at 75 baits/
km2 and 750-m flight-line spacing in the study area. Animal sampling occurred during 10-d intervals
pre- and post-ORV during 2012–14 within eight study cells: four northern cells had a history of ORV
with a different vaccine for 3 or more years prior and four southern cells were ORV naive. Baseline
raccoon RVNA seroprevalence was 27.3% (n¼1,079, 95% confidence interval [CI]: 24.8–30.1) before
ORV in 2012. Raccoon RVNA seroprevalence averaged 68.5% (n¼1,551, 95% CI: 66.2–70.8) post-ORV
during the 3-yr study. The RVNA seroprevalence levels in this study were considered to be adequate for
stopping raccoon RV transmission and supported and expanded the results from a West Virginia field
trial, as well as earlier evaluations along the Canada–US border.
Key words: Field trial, ONRAB, oral rabies vaccination, rabies, raccoon.
INTRODUCTION
Rabies virus (RV) has been enzootic in
raccoon (Procyon lotor) populations in the US
at least since the late 1940s, with an original
focus in the state of Florida (McLean 1971;
Bigler et al. 1973). The raccoon RV focus
expanded into neighboring states of the
southeastern US during the 1960s–70s, but
translocation of rabid raccoons in the late
1970s seeded an epizootic that rapidly spread
across the US Eastern Seaboard (Nettles et al.
1979; Rupprecht and Smith 1994). With an
interest in developing and evaluating inter-
vention tools to combat further spread of RV
in raccoon populations, the first field trials for
oral rabies vaccination (ORV) in the US
occurred in Virginia during 1990 (Hanlon et
al. 1998), Pennsylvania during 1991 (Hanlon
and Rupprecht 1998), New Jersey during
1992–93 (Roscoe et al. 1998), followed by
Massachusetts (Robbins et al. 1998) and New
York (Hanlon and Rupprecht 1998) during
1994, and Florida during 1995 (Olson et al.
2000). Under the US Department of Agricul-
ture, Animal and Plant Health Inspection
Service, Wildlife Services, National Rabies
Management Program (NRMP), coordinated
ORV was initiated in 1995. Through 2003, the
geographic scale and intensity of ORV target-
ing wild mesocarnivores expanded significant-
ly (Slate et al. 2005). The broad-scale
landscape application of ORV, with support-
ing contingency actions, effectively halted the
westward spread of raccoon RV. However, RV
neutralizing antibody (RVNA) seroprevalence
averaging 30% in raccoon populations is likely
inadequate to eliminate RV (Slate et al. 2009;
Rees et al. 2013).
The only ORV product licensed for use with
wildlife in the US is a live recombinant
vaccinia virus expressing the rabies virus
glycoprotein, contained in a sachet with a
fishmeal attractant matrix (RABORAL V-
RGt, hereafter V-RG; Boehringer Ingelheim
Animal Health, Athens, Georgia, USA; Maki
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et al. 2017). To evaluate additional tools for
ORV with the goal of eliminating raccoon RV
in the US, and as part of cooperative efforts
under the North American Rabies Manage-
ment Plan, the NRMP turned its focus to a
Canadian ORV product that had been suc-
cessful in controlling circulation of an Arctic
fox (Vulpes lagopus) RV variant in striped
skunk (Mephitis mephitis) populations in
Ontario (Rosatte et al. 2011). This product is
a live recombinant human adenovirus express-
ing the rabies virus glycoprotein (AdRG1.3),
enclosed in a blister pack with a sweet
attractant matrix that contains 100 mg of
tetracycline hydrochloride (TTCC) biomarker
(Ontario Rabies Vaccine Bait, hereafter ON-
RAB; Artemis Technologies, Inc., Guelph,
Ontario, Canada; Graham and Prevec 1992;
Rosatte et al. 2009). Two cross-border coop-
erative studies between Canada and the US
compared the change in target population
RVNA seroprevalence before and after ORV:
1) using ONRAB in New Brunswick versus V-
RG in Maine under an application rate of 75
baits/km2 (Fehlner-Gardiner et al. 2012), and
2) using ONRAB in Quebec versus V-RG in
Vermont under an application rate of 150
baits/km2 (Mainguy et al. 2013). In both
studies, greater RVNA seroprevalence was
observed among raccoons from ONRAB ORV
areas in Canada compared with raccoons from
V-RG ORV areas in the US (Fehlner-
Gardiner et al. 2012; Mainguy et al. 2013).
The cross-border comparison studies led to
interest in experimental evaluation of ONRAB
in the US. The first field trial of ONRAB in
the US occurred during 2011 in West Virginia,
in an ORV-naive area (Slate et al. 2014). This
field trial indicated a significant increase in
RVNA from background levels in raccoon
populations, with post-ORV levels also higher
than those typically observed from nearby
areas treated with V-RG at the same bait
application rates (Slate et al. 2014).
The experimental evaluation of ONRAB
was then expanded to other regions of the US,
including areas with a history of V-RG baiting.
One trial initiated during 2012 occurred in
northern New York, Vermont, and New
Hampshire. This area has been an important
focus for rabies control, as it shares a border
with Quebec, Canada, and has been identified
as a high-risk area for reintroduction of
raccoon RV into Canada. We describe the
results of a 3-yr field trial of ONRAB in
northern New York, Vermont, and New
Hampshire, which included study areas naive
to ORV and areas previously baited with V-
RG. Our objectives were to evaluate the
impact of ORV using ONRAB, measured by
increases in RVNA seroprevalence above
baseline values in free-ranging raccoon pop-
ulations, and to identify how the induction of
RVNA (as an index to immunity) was affected
by raccoon age and sex, while controlling for
prior treatment history of areas and ORV
application.
MATERIALS AND METHODS
Study area and design
The study area encompassed three states and
nine counties in the northeastern US: New York
(Clinton and Essex counties), Vermont (Addison,
Caledonia, Chittenden, Essex, Franklin, and
Lamoille counties), and New Hampshire (Grafton
County). Eight 132-km2 study cells were separat-
ed by at least 1.8 km and buffered by at least 4.7
km from unbaited areas or where bordered by
Lake Champlain (Fig. 1). Four northern study
cells had been baited previously with V-RG at
least from 2007 to 2011. The overall macrohabitat
composition of these study cells was 59% forested,
20% agriculture, 10% developed, and 11%
wetland or water. Four study cells were estab-
lished farther south, in areas that were ORV naı¨ve
from 2009 to 2011 (two cells) or completely ORV
naı¨ve (two cells). Their macrohabitat composition
was 60% forested, 26% agriculture, 6% devel-
oped, and 8% wetland/water. The macrohabitat
compositions were calculated by grouping the
2011 National Land Cover Database into catego-
ries on the basis of land class values: forested
(values 41, 42, 43, 52), agriculture (values 71, 81,
82), developed (values 21, 22, 23, 24), wetland or
water (values 11, 90, 95), and other (value 31;
Homer et al. 2015).
Given the geographic and political importance,
a 16-km-wide portion of the ORV zone along the
Canadian border was baited with ONRAB at 150
baits/km2 (Fig. 1), but this area was not evaluated
in this study. In the remainder of the ORV zone,
ONRAB baits were distributed at 75 baits/km2
either aerially, along parallel flight lines spaced at
750-m intervals, or by hand in suburban and
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urban areas where aerial distribution was opera-
tionally impractical or could result in human
safety concerns (Table 1). Baits had a warning
label with a toll-free number to facilitate commu-
nication of potential vaccine exposures to the New
York State Department of Health (NYSDOH) or
Wildlife Services (in Vermont and New Hamp-
shire).
Animal sampling
Trapping occurred pre- and post-ORV during
2012–14. Random points, generated using either
Hawth’s tools (Beyer 2004) in 2012 or Geospatial
Modeling Environment (v 0.7.3.0; Beyer 2012) in
2013 and 2014, were used to guide placement of
150 traps in each cell. The same points were used
for pre- and post-ORV trapping efforts within a
year, with new points generated each year.
Animals were live-trapped using cage traps
(Tomahawk Live Trap, LLC, Hazelhurst, Wis-
consin, USA). Traps were set for 10 consecutive
days and checked daily. All nontarget species were
released at the point of capture. Captured target
species (e.g., raccoons, striped skunks, red foxes
[Vulpes vulpes], gray foxes [Urocyon cinereoar-
genteus], coyotes [Canis latrans], and fishers
[Martes pennanti]) were anesthetized using a 5:1
mixture of ketamine:xylazine (i.e., 10 mg/kg
ketamine and 2 mg/kg xylazine) to determine sex
(male or female), relative age (adult or juvenile),
weight (kg), to assess general body condition, to
collect a blood sample from a peripheral vein, to
extract a first premolar tooth, and to apply a
uniquely numbered metal tag (National Band and
Tag Company, Newport, Kentucky, USA) in each
ear. Recaptured target animals were resampled,
unless the recapture event occurred within a 10-d
sampling period. For recaptures within a sampling
period, target animals were released at the point
of capture without resampling. Target animals
exhibiting normal behavior before anesthesia and
in good general body condition were released at
FIGURE 1. Study area where oral rabies vaccination (ORV) using Ontario Rabies Vaccine Baits (ONRAB) at
75 baits/km2 was evaluated in the northeastern USA during 2012–14. Northern cells (PBG01, 02, 04, 05) had
been baited with vaccinia–rabies glycoprotein before 2012. Southern cells (PBG03, 06, 07, 08) were naı¨ve to
ORV before 2012. White areas within the gray ORV zones are .500 m in elevation and were not baited because
of negligible raccoon presence in those habitats on the basis of previous studies.
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the point of capture after recovery from anesthe-
sia. Animals exhibiting abnormal behavior or with
suspect lesions or wounds were euthanized in
accordance with the American Veterinary Medical
Association’s Panel on Euthanasia recommenda-
tions (e.g., two-stage chemical euthanasia with
pentobarbital, sodium pentobarbital, or potassium
chloride products; AVMA 2013). Brain-stem
tissues were collected in Vermont and New
Hampshire, whereas whole heads were collected
in New York. In New York, animals suspected of
having rabies were tested by NYSDOH Rabies
Laboratory using the direct fluorescent antibody
test (Centers for Disease Control and Prevention
2017). In Vermont and New Hampshire, animals
suspected of having rabies were tested by the
Vermont Department of Health Laboratory using
the direct fluorescent antibody test. For all
positive cases, RV variant typing was performed
by the NYSDOH Rabies Laboratory (Szanto et al.
2011). Serum samples were separated from whole
blood by centrifugation on the day of capture and
stored in labeled cryovials at25 C to70 C until
analysis.
RVNA determination
Serum RVNA titers were determined using a
modified neutralization test (Trimarchi et al.
1996) at the NYSDOH Rabies Laboratory. The
cutoff for determining a RVNA seropositive
serum was 0.125 IU/mL, on the basis of
comparison with a standard rabies immune
globulin control, which is the sensitivity threshold
for this test. This cutoff level is slightly higher
than RVNA titers that have been associated with
survivorship against a RV challenge in an exper-
imental study with raccoons (i.e., 0.05 to 0.11 IU/
mL; Blanton et al. 2018). We also considered a
higher RVNA cutoff of 0.5 IU/mL as a recognized
level of immunity that has been considered a
surrogate of protection against RV challenge in
raccoons and other wildlife (Moore et al. 2017;
Blanton et al. 2018). Samples with test values less
than the cutoff were coded as seronegative. At the
0.125 IU/mL cutoff, a total of 59 raccoon and four
skunk samples, constituting 1% of all samples,
could not be evaluated (e.g., samples reported
with RVNA less than 0.25 IU/mL) because of
poor quality and were excluded from further
analyses. At the 0.5 IU/mL cutoff, only six raccoon
sera reported with RVNA less than 1 IU/mL were
excluded.
A subset of 325 raccoon sera that tested within
the range of 0.125–0.5 IU/mL at the NYSDOH
laboratory were independently tested at Kansas
State University to quantify RVNA titers in IU/
mL using a standard rapid fluorescent focus
inhibition test (Yager and Moore 2015), and in
duplicate at the US Department of Agriculture
National Wildlife Research Center (Fort Collins,
Colorado, USA) to quantify percent inhibition
values using a commercial blocking enzyme-
linked immunosorbent assay (BioPro Rabies
ELISA, OK Servis, Prague, Czech Republic)
following the manufacturer’s instructions (see
Supplementary Material Table S1).
Tetracycline biomarker and age determination
Animal teeth were shipped to Matson’s Labo-
ratory LLC (Manhattan, Montana, USA) for
TTCC detection and age determination. An
ultraviolet light at3100 magnification with a Leitz
compound microscope (Leica Microsystems
GmbH, Wetzlar, Germany) was used to detect
TTCC. A total of 477 raccoons and 30 striped
skunks were not evaluated for TTCC (11.0% and
14.9% of records, respectively). The cementum
annuli count method was used for determining
ages (Johnston et al. 1987). Animal body size,
weight, and reproductive status were also used in
the field for classifying individuals as adults or
juveniles. Whenever ages determined by cemen-
tum annuli were available, they were preferen-
tially used as the most accurate estimate of animal
age (see Supplementary Material Fig. S1). Rela-
tive age data (i.e., adult or juvenile) were available
TABLE 1. Number of Ontario Rabies Vaccine Baits and area (km2) subjected to oral rabies vaccination (ORV),
by aerial or ground distribution, at 75 baits/km2 in the northeastern USA during 2012–14. Dates of ORV and
associated pre- and post-ORV target animal sampling of study cells are listed for each year.
Year
Aerial Ground Trapping dates
n Baits Area (km2) n Baits Area (km2) ORV dates Pre-ORV Post-ORV
2012 377,885 6,782 17,730 314 13–23 August 10 July–5 August 24 September–5 October
2013 358,265 6,782 17,358 308 20–24 August 10 July–2 August 19–31 October
2014 384,528 7,079 17,251 303 12–19 August 24 June–1 August 23 September–3 October
Total 1,120,678 20,643 52,339 925
Mean 373,559 6,881 17,446 308
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for 415 raccoons and 42 striped skunks. In either
case, juvenile refers to an animal less than 1 yr of
age.
Statistical methods
We conducted two types of generalized linear
mixed model (GLMM) analyses, one at the
individual-animal level and one at the within-cell
population level. Only raccoons were included in
analyses, and recaptured individuals were includ-
ed in both. We used package lme4 in RStudio (v
0.99.903; Bates et al. 2015). Study cell was treated
as a random effect and nested within location
(treatment history before 2012). Model goodness
of fit was assessed using the marginalized and
conditional R2 (Nakagawa and Schielzeth 2013).
We performed model selection using Akaike’s
information criterion corrected for small sample
sizes (AICc; Burnham and Anderson 2002) and
considered RVNA seroprevalence estimates using
low (0.125 IU/mL) and high (0.5 IU/mL) cutoffs.
For the individual-level GLMM, we also
treated year as a random effect. The RVNA status
of individual raccoons was the binomial response
variable, with sex (male or female), age (years),
sampling period (pre- or post-ORV), and cell
location (southern naı¨ve or northern historic V-
RG) as fixed effects. To account for missing sex
classifications for 31 raccoons, we converted sex to
a numeric vector with males as 1, females as 0,
and missing as 0.5. We used age estimated from
premolars when available. From a total of 415
raccoons missing an age determined from a
premolar, we assigned 86 raccoons classified in
the field as juveniles age 0 yr, and 329 raccoons
classified in the field as adults age 2.62 yr (i.e., the
mean of a negative binomial distribution fit to the
adult data). The candidate models with a change
in Akaike’s information criterion corrected for
small sample sizes of less than two from the top
model were recognized as competitive models.
For the population-level GLMM, the proportional
difference in the RVNA seroprevalence or TTCC
prevalence of the raccoon population pre- and
post-ORV within each cell and year were the
continuous response variables, with fixed effects
of location and year. Exact 95% confidence
interval (CI) were calculated on estimated pro-
portions. Finally, we generated descriptive statis-
tics for recaptured raccoons, with a focus on
RVNA status within and across years.
RESULTS
Across the 3 yr of the field trial, a total of
4,505 target animals were captured and
sampled for RVNA (Table 2), of which
94.8% (4,269/4,505) were raccoons, 4.4%
(198/4,505) were striped skunks, 0.4% (19/
4,505) were fishers, 0.3% (12/4,505) were gray
foxes, 0.09% (4/4,505) were red foxes, and
0.07% (3/4,505) were coyotes. Among rac-
coons, 3,449 records were unique and 820
records were from recaptured individuals.
The number of serum test results was greater
at the higher RVNA cutoff (n¼4,562, Table
S2), where an additional 53 raccoon and four
skunk sera were evaluated. Forty-one target
animals were found dead or were euthanized
during the study and 61% (25/41) were tested
for RV antigens. Among euthanized target
animals, 83% (20/24) were tested for RV
antigens. Thirteen of the euthanized animals
had abnormal behavior or a lesion leading to a
suspicion of rabies, but only 1 of the 20 adult
male raccoons tested positive with raccoon RV
variant. This raccoon was captured during the
2012 pre-ORV period.
The RVNA seroprevalence among the
raccoon population was 27.3% (295/1,079,
95% CI: 24.8–30.1) before the distribution
of ONRAB in 2012. The raccoons in the
northern cells demonstrated higher RVNA
seroprevalence at 29.9% (218/728, 95% CI:
26.7–33.4) compared with 21.9% (77/351,
95% CI: 17.9–26.6) in raccoons from southern
cells (Table 2). Raccoons in the northern cells
always had lower RVNA seroprevalences
compared with raccoons from the southern
cells post-ORV during each year, although the
difference between locations was marginal at
the higher RVNA cutoff (Table 2 and Table
S2). The overall post-ORV RVNA seropreva-
lence was 68.5% (1,063/1,551, 95% CI: 66.2–
70.8) in the raccoon population during this
study, or 53.4% (844/1,581, 95% CI: 50.9–
55.8) considering the higher RVNA cutoff.
The top population-level GLMM of RVNA
seroconversion to ORV included a year effect
(Table 3). The marginalized R2 and the
conditional R2 of the model were 0.626 and
0.740, respectively. The impact of the annual
ONRAB ORV decreased across the 3-yr study
(Fig. 2). The RVNA seroprevalence in the
raccoon population increased by an average of
42% after ONRAB ORV during year 1 and
20% during year 2, but no further gains were
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observed during year 3. Model selection
results were similar considering a higher
RVNA cutoff (Table S3). At the higher cutoff,
RVNA seroprevalence in the raccoon popula-
tion increased by an average of 34% during
year 1, 21% during year 2, and 9% during year
3 (Fig. S2). The top population-level model of
the change in TTCC prevalence among
raccoons included a year effect (Table S4),
with a marginalized and conditional R2 of
0.584. The TTCC prevalence in the raccoon
population increased by an average of 46%
during year 1, 29% during year 2, and 12%
during year 3 (Fig. S3).
For the individual-level analysis (Table S5),
there were nine competitive models for the
probability of an individual raccoon being
RVNA seropositive (Table S6). The top model
(m100) included two-way interactions of
period3sex, period3age, and period3location,
with a marginalized and conditional R2 of
0.136 and 0.212, respectively. Female and
male raccoons were more likely to be
seropositive during post-ORV sampling peri-
ods, with no difference between the sexes
within periods (Fig. 3). Older raccoons were
more likely to be seropositive, especially
during the pre-ORV period (Fig. 4). Raccoons
in the southern cells were more likely to be
seropositive than raccoons in the northern
TABLE 3. Raccoon (Procyon lotor) population-level linear mixed-model selection for rabies virus neutralizing
antibody (RVNA) response to oral rabies vaccination with Ontario Rabies Vaccine Baits at 75 baits/km2 in the
northeastern USA during 2012–14, on the basis of Akaike’s information criterion corrected for small sample sizes
(AICc) and a RVNA cutoff of 0.125 IU/mL. Regarding location, four southern study cells were naı¨ve to oral
rabies vaccination and four northern study cells were historically baited with vaccinia–rabies glycoprotein before
2012.
Model Ka AICcb DAICcc xd 2 Log (L)e
Year 5 14.53 0 0.63 13.93
Year3locationþyearþlocation 7 12.43 2.10 0.22 16.72
Yearþlocation 6 11.69 2.85 0.15 14.31
Intercept 4f 7.20 21.74 0 1.45
Location 5 9.98 24.51 0 1.68
a K¼ number of parameters in the model including random effects and variance.
b AICc¼ second-order Akaike’s information criterion.
c DAICc ¼ difference in AICc value from the top model.
d x ¼ Akaike weight or relative support for a given model.
e 2 Log (L) ¼ twice the negative log-likelihood value.
f The intercept model has four parameters: 1) intercept parameter of B0, 2) random effect of cell, 3) random effect of location, and 4)
variance parameter for the normal distribution.
FIGURE 2. Difference in the rabies virus neutral-
izing antibody (RVNA) seropositive proportion of
raccoons (Procyon lotor) between pre- and post-oral
rabies vaccination (ORV) for each cell and year for
the evaluation of Ontario Rabies Vaccine Bait
distribution at 75 baits/km2 in the northeastern
USA during 2012–14, using a RVNA cutoff of 0.125
IU/mL. Southern study cells (hollow circles) were
naı¨ve to ORV before 2012, and northern cells (filled
triangles) had been baited with vaccinia–rabies
glycoprotein before 2012.
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cells, regardless of sampling period (Fig. 5).
There were seven competitive models at the
higher RVNA cutoff, and the top model
(m095) included two-way interactions of
period3sex, period3age, age3sex, and loca-
tion3sex (Table S7), with a marginalized and
conditional R2 of 0.136 and 0.194, respective-
ly. The period3sex and period3age trends
were the same as reported for the lower
cutoff. Male and female raccoons were more
likely to be seropositive in the southern
compared with northern locations, and the
probability of being seropositive increased
with age in both male and female raccoons.
Among recaptured raccoons, 50.3% (343/
682, 95% CI: 46.6–54.0) were RVNA negative
upon initial capture, with 58.3% (200/343,
95% CI: 53.0–63.4) of the seronegative
raccoons seroconverting between successive
capture events. Higher levels of seroconver-
sion were documented among raccoons re-
captured during post- compared with pre-
ORV periods (Table 4). For raccoons that
were RVNA seropositive upon initial capture,
82.6% (280/339, 95% CI: 78.2–86.3) were
seropositive upon recapture.
DISCUSSION
The distribution of ONRAB during 2012 at
75 baits/km2 and 750-m flight-line spacing in
the northeastern US field trial achieved a
FIGURE 4. Proportion of raccoons (Procyon lotor)
seropositive for rabies virus neutralizing antibodies
(RVNA) across yearly age classes during pre- (white
bars) and post-oral rabies vaccination (ORV; gray bars)
sampling periods for the evaluation of Ontario Rabies
Vaccine Bait distribution at 75 baits/km2 in the
northeastern USA during 2012–14, using a RVNA
cutoff of 0.125 IU/mL. Error bars reflect 95%
confidence intervals on estimated proportions.
FIGURE 5. Proportion of raccoons (Procyon lotor)
seropositive for rabies virus neutralizing antibodies
(RVNA) in southern and northern locations during
pre- (white bars) and post-oral rabies vaccination
(ORV; gray bars) sampling periods for the evaluation
of Ontario Rabies Vaccine Bait distribution at 75 baits/
km2 in the northeastern USA during 2012–14, using a
RVNA cutoff of 0.125 IU/mL. Southern locations were
naı¨ve to ORV before 2012, and northern locations had
been baited with vaccinia–rabies glycoprotein before
2012. Error bars reflect 95% confidence intervals on
estimated proportions.
FIGURE 3. Proportion of male and female raccoons
(Procyon lotor) seropositive for rabies virus neutraliz-
ing antibodies (RVNA) during pre- (white bars) and
post-oral rabies vaccination (ORV; gray bars) sampling
periods for the evaluation of Ontario Rabies Vaccine
Bait distribution at 75 baits/km2 in the northeastern
USA during 2012–14, using a RVNA cutoff of 0.125
IU/mL. Error bars reflect 95% confidence intervals on
estimated proportions.
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post-ORV RVNA seroprevalence of 73.4%
(160/218, 95% CI: 67.2–78.8) among the
ORV-naı¨ve raccoon population, which is the
highest observed by Wildlife Services in an
ORV-naı¨ve area with similar treatment (Slate
et al. 2014). The distribution of ONRAB
during 2012 also achieved a post-ORV RVNA
seroprevalence of 65.3% (277/424, 95% CI:
60.7–69.7) among the raccoon population with
a history of prior ORV. Estimated RVNA
seroprevalence was uniformly lower using a
higher cutoff of 0.5 IU/mL, but these values
were comparable with the levels observed in
raccoon populations following the distribution
of ONRAB at 75 baits/km2 in an area
previously treated with ORV in southwestern
Ontario (Rosatte et al. 2009) and in an area
with a limited history of trap–vaccinate–
release in New Brunswick (Fehlner-Gardiner
et al. 2012).
Baseline RVNA seroprevalence was 21.9%
and 29.9% among raccoons sampled from
southern and northern cells, respectively,
before ONRAB bait distribution in 2012. At
a higher RVNA cutoff, these estimates were
8.8% (31/351, 95% CI: 6.3–12.3) and 16.2%
(119/733, 95% CI: 13.7–19.1) in southern and
northern cells, respectively. Regardless of the
RVNA cutoff used, it is well recognized that
background levels of RVNA in raccoon
populations can result from apparently suble-
thal exposures to RV (i.e., abortive infections;
McLean 1971; Bigler et al. 1973; Slate et al.
2014). One of the four southern cells had
RVNA seroprevalence of 36.9% (55/149, 95%
CI: 29.6–44.9) before ORV in 2012 and
evidence of an elevated number of rabies
cases during the year before ORV, whereas
raccoons in the other three southern cells had
9% (4/46, 95% CI: 3–20) to 12.0% (12/100,
95% CI: 7.0–19.8) RVNA seroprevalence. Of
raccoons sampled from the southern cells
before ONRAB distribution in 2012, 27% (81/
304) were juveniles and 22% (18/81, 95% CI:
15–32) were RVNA seropositive, compared
with 24.2% (54/223, 95% CI: 19.1–30.3) of
adults. Thus, even if passive maternal RVNAs
were present in the juvenile cohort, it does
not appear that it biased the seroprevalence
estimate for the southern cells before ONRAB
distribution. In contrast, the four northern
cells had similar RVNA seroprevalence before
ONRAB distribution (range of 26.1% [47/180,
95% CI: 20.2–33.0] up to 33.0% [61/185, 95%
CI: 26.6–40.0]) and comparable levels with
the national average of 30% from V-RG-
baited areas in the US that consider a RVNA
cutoff of 0.06 IU/mL (Slate et al. 2009).
Even though TTCC deposition may be
lower in premolar teeth than in canine teeth
or mandibular bone (Algeo et al. 2013; Slate et
al. 2014), the population TTCC response was
consistent with the RVNA analysis in estimat-
ing the fractions of the raccoon population
affected by ORV in this study. The top
population-level models of RVNA seroconver-
sion and TTCC response during the field trial
did not include location, and thus were similar
TABLE 4. Rabies virus neutralizing antibody seroprevalence (%) and corresponding sample size (n) for 343
captured and recaptured raccoons (Procyon lotor) that were seronegative upon initial capture on the basis of a
cutoff of 0.125 IU/mL, by sampling period relative to oral rabies vaccination (ORV) with Ontario Rabies Vaccine
Baits at 75 baits/km2 in the northeastern USA during 201214.a
Year captured
Year recaptured
2012 2013 2014
Post-ORV Pre-ORV Post-ORV Pre-ORV Post-ORV
% n % n % n % n % n
2012 62 131 53 75 86 7 63 19 91 11
2013 — — — — 60 30 29 24 88 8
2014 — — — — — — — — 50 38
a —¼ not applicable.
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across all study cells (Fig. 2 and Figs. S2, S3).
Pooling all years of data, the fraction of RVNA
seropositive raccoons was greater in the
southern cells compared with the northern
cells during both sampling periods. This may
be an artifact of differences in raccoon
densities between the locations rather than a
legacy effect of treatment history before 2012.
Across all 3 yr, identical trapping effort in the
northern cells tended to result in the capture
of twice as many raccoons per sampling
period compared with the southern cells
(mean of 114 compared with 64). Since the
baiting density was the same for all cells, there
may have been more baits available to
raccoons in the southern cells given a
potentially lower density of raccoons, and
assuming nontarget competition for baits and
other potential environmental factors were
similar across cells and years. This explanation
is consistent with another study, which
reported that increasing raccoon abundance
was negatively associated with the probability
of an individual raccoon being seropositive for
RV antibody (Mainguy et al. 2012).
We present evidence of a saturating effect
in RVNA seroconversion in the raccoon
population after successive annual ORV cam-
paigns. Similar trends have been reported
previously (Sattler et al. 2009; Mainguy et al.
2012). Results observed in this study may be
specific to the relatively large size of the area
baited (about 7,189 km2). Smaller ORV areas
may be subject to greater edge effects, and
thus greater external disease pressure and
immigration of individuals from unbaited
areas, leading to longer delays in seropreva-
lence saturation and reduction of case burden.
During this study, older raccoons were more
likely to be seropositive than younger rac-
coons. An increasing RV antibody seropreva-
lence with raccoon age was also reported in a
prior study investigating the use of ONRAB in
southern Quebec (Mainguy et al. 2012).
Nevertheless, over 85% of raccoons sampled
in the current study were equal to or less than
3 yr old. Thus, significant turnover in the
susceptible fraction of the raccoon population
is possible 3 yr after an ORV campaign,
potentially framing a minimum annual ORV
program of 2 to 3 yr to achieve herd immunity
saturation for elimination on larger land
masses.
A simulation study concluded that raccoon
population immunity of 60% leads to a
dramatic reduction in rabies cases, even under
varying assumptions about habitat quality and
population connectivity (Rees et al. 2013). A
more recent simulation study using empiri-
cally derived contact data found that when RV
was introduced at the start of the breeding
season in a ‘‘suburban’’ (i.e., high-density)
raccoon population, vaccination coverage in
excess of 80% would be necessary to prevent
an outbreak (Reynolds et al. 2015). There is
likely variation in coverage necessary between
rural and suburban settings, where raccoon
densities vary from low to high, respectively,
with potential impacts for contact behavior
and disease spread (Hadidian et al. 2010). A
summary of 58 studies conducted by the
NRMP in the northeastern US study area
during 1997–2010 determined a mean rac-
coon abundance index of 8.0 (range of 2.1–17)
raccoons/km2 in agricultural mixed-forest
habitats. Simulation modeling tools, which
can further examine the impacts of variable
host densities, in addition to habitat-based
contact and movement across complex land-
scapes, will be informative for managers
planning ORV interventions (Elmore et al.
2017; Tardy et al. 2018).
The RVNA seroprevalence levels docu-
mented in this study are likely adequate for
stopping RV transmission and support and
expand upon the results from the West
Virginia ONRAB field trial (Slate et al.
2014), as well as earlier cross-border evalua-
tions (Fehlner-Gardiner et al. 2012; Mainguy
et al. 2013). Raccoon RV variant cases have
decreased in the study area ORV zone since
the distribution of ONRAB began in 2012
(Fig. 1). Before ONRAB distribution (during
2011 and the summer of 2012), there were 27
confirmed cases of raccoon rabies throughout
the zone and in 2016 there were only two
cases. However, maintaining robust enhanced
rabies surveillance in this region will yield
further evidence to the effectiveness of this
baiting strategy. Although none of the study
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cells was located in the area where ONRAB
was applied at 150 baits/km2, we speculate
that the levels of RVNA in the raccoon
population in the higher bait density area
were at least as high as those observed in the
area baited at 75 baits/km2 during this study.
Taken together, the levels of RVNA achieved
in the raccoon population baited with ON-
RAB during this study should establish
sufficient raccoon population immunity to
disrupt the circulation of raccoon RV in
agricultural mixed-forest habitats of this re-
gion.
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